An Update on the Potential of Mesenchymal Stem Cell Therapy for Cutaneous Diseases.

Stem Cells Int

Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and Translational Research, Guangdong Medical University, Dongguan 523808, China.

Published: January 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mesenchymal stem or stromal cells (MSCs) are nonhematopoietic postnatal stem cells with self-renewal, multipotent differentiation, and potent immunomodulatory and anti-inflammatory capabilities, thus playing an important role in tissue repair and regeneration. Numerous clinical and preclinical studies have demonstrated the potential application of MSCs in the treatment of tissue inflammation and immune diseases, including inflammatory skin diseases. Therefore, understanding the biological and immunological characteristics of MSCs is important to standardize and optimize MSC-based regenerative therapy. In this review, we highlight the mechanisms underlying MSC-mediated immunomodulation and tissue repair/regeneration and present the latest development of MSC-based clinical trials on cutaneous diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806381PMC
http://dx.doi.org/10.1155/2021/8834590DOI Listing

Publication Analysis

Top Keywords

mesenchymal stem
8
cutaneous diseases
8
update potential
4
potential mesenchymal
4
stem cell
4
cell therapy
4
therapy cutaneous
4
diseases
4
diseases mesenchymal
4
stem stromal
4

Similar Publications

Tumor necrosis factor-alpha (TNF-α) is a cytokine involved in the immune-inflammatory response. It can induce an odontoblastic phenotype and enhance biomineralization in dental pulp mesenchymal stem cells but does not have the same effect on osteoblasts. The reasons for this differential response, despite the shared lineage of these cell types, are not yet clear.

View Article and Find Full Text PDF

Crosstalk between leukemic cells and their surrounding mesenchymal stromal cells (MSCs) in the bone marrow microenvironment is crucial for the pathogenesis of myelodysplastic syndromes (MDS) and is mediated by extracellular vesicles (EVs). The EV-specific miRNAs derived from MDS-MSCs remain poorly explored. EVs isolated from HS-5, an immortalized stromal cell line, promoted the proliferation and 5-azacytidine (AZA) resistance of SKM-1 cells.

View Article and Find Full Text PDF

Botanical Nanovesicles Boost Mesenchymal Stem Cell Therapy: Next-Gen Advanced Therapy Medicinal Products for Spinal Cord Injury.

Tissue Eng Part B Rev

September 2025

Department of Pharmaceutics School of Pharmacy, Centre for Nano Drug/Gene Delivery and Tissue Engineering, Jiangsu University, Zhenjiang, People's Republic of China.

The poor prognosis constitutes a significant difficulty for spinal cord injury (SCI) individuals. Although mesenchymal stem cells (MSCs) hold promises as advanced therapy medicinal products (ATMPs) for SCI patients, challenges such as Good Manufacturing Practice-compliant manufacturing, cellular senescence, and limited therapeutic efficacy continue to hinder their clinical translation. Recent advances have identified botanical nanovesicles (BNs) as potent bioactive mediators capable of "priming" MSCs to self-rejuvenate, augment paracrine effect, and establish inflammatory tolerance.

View Article and Find Full Text PDF

Deciphering the molecular landscape of acute myeloid leukemia initiation and relapse: a systems biology approach.

Med Oncol

September 2025

Division of Hematology and Blood Bank, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Acute Myeloid Leukemia (AML) patient-derived Mesenchymal Stem Cells (MSCs) behave differently than normal ones, creating a more protective environment for leukemia cells, making relapse harder to prevent. This study aimed to identify prognostic biomarkers and elucidate relevant biological pathways in AML by leveraging microarray data and advanced bioinformatics techniques. We retrieved the GSE122917 dataset from the NCBI Gene Expression Omnibus and performed differential expression analysis (DEA) within R Studio to identify differentially expressed genes (DEGs) among healthy donors, newly diagnosed AML patients, and relapsed AML patients.

View Article and Find Full Text PDF

Background: Several studies have suggested that adult human dermal fibroblasts (HDFa) may be a potential alternative source to mesenchymal stem cells for cell therapies. This study aims to characterize HDFa, adipose-derived stem cells (ADMSCs) and dental pulp stem cells (DPSCs) to investigate their proliferation, differentiation potential, mitochondrial respiration, and metabolomic profile. We identified molecules and characteristics that would differentiate MSCs from different sources or confirm their uniformity.

View Article and Find Full Text PDF